Stoke Therapeutics, Inc. — Form 10-Q
Filed August 3, 2026 · analyzed by the Periodic Agent
10-Q
▼ Likely negative
significance 38/100
What the filing says
Stoke amended employment agreements for three executives on July 21, 2026. CEO Ian Smith's severance extended from 12 to 18 months of base salary ($715,000/year) plus 18 months COBRA; CFO Thomas Leggett's severance increased from 9 to 12 months of base salary ($475,000/year) plus 12 months COBRA; CCO Jason Hoitt's severance increased from 9 to 12 months of base salary ($456,000/year) plus 12 months COBRA. Total severance commitments expanded by approximately $1.1M–$1.3M in present value.
Why this rating
Severance enhancements increase labor liabilities 30–50% for top 3 executives (~0.2% of market cap), routine cost, no change to business operations or strategy.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.